title: [A case of complete response for advanced gastric cancer with liver metastasis treated with combination chemotherapy of weekly paclitaxel and doxifluridine].
abstract: A 68-year-old man underwent total gastrectomy for Type 3 gastric cancer with liver metastasis. The final finding was T3(SE), N1, H1, P0, CY0(class IV), Stage IV, Cur C. After surgery, he was treated with combination chemotherapy of weekly paclitaxel(PTX)/doxifluridine(5'-DFUR). Paclitaxel was administered at a dose of 80 mg/m(2) on day 1, 8 and 15, and doxifluridine was orally administered at a dose of 533 mg/m(2) day for five days followed by withdrawal for two days. This regimen was repeated every four weeks. After 2 courses, the tumor marker level normalized, and the size of the liver metastasis was remarkably decreased. After 5 courses, a CT scan revealed the liver metastasis had disappeared, and he has now survived without recurrence after the disappearance of the liver metastasis. No severe adverse reactions were observed, and the man can be treated as an outpatient. This therapy may thus be effective in the treatment of advanced gastric cancer following non-curative operation.
authors.affiliation: Dept. of Surgery, Ojiya General Hospital, Japan.
authors.forename: Toshio
authors.initials: T
authors.lastname: Okabe
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Ohya
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Tago
authors.forename: Osamu
authors.initials: O
authors.lastname: Totsuka
authors.forename: Yuki
authors.initials: Y
authors.lastname: Numaga
authors.forename: Toru
authors.initials: T
authors.lastname: Higuchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Iesato
authors.forename: Tadahiro
authors.initials: T
authors.lastname: Yokomori
authors.forename: Susumu
authors.initials: S
authors.lastname: Kawate
authors.forename: Izumi
authors.initials: I
authors.lastname: Takeyoshi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D005467:Floxuridine / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D009367:Neoplasm Staging; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D005467:Floxuridine; D017239:Paclitaxel; C025034:doxifluridine